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Abstract
Background: An inflammatory insult following middle cerebral artery occlusion (MCAO) is
associated with a predisposition to develop a deleterious autoimmune response to the brain
antigen myelin basic protein (MBP). Induction of immunologic tolerance to brain antigens prior to
MCAO prevents this deleterious autoimmune response and is associated with better functional
outcome early after stroke. In this study, we sought to determine the long term immunologic
consequences of experimental stroke and induction of mucosal tolerance.
Methods: Male Lewis rats were tolerized to MBP or ovalbumin (OVA) by intranasal administration
prior to MCAO and administration of lipopolysaccharide (LPS). Neurological outcome was
assessed at set points after MCAO and animals sacrificed at 3 months; the immune response to
MBP in brain and spleen was determined using ELISPOT assay and degree of cellular inflammatory
brain infiltrate assessed by immunocytochemistry.
Results: Animals that developed a pro-inflammatory (TH1) response to MBP experienced worse
outcome, while those that developed a regulatory response (TREG) experienced better outcome.
A TREG response in spleen was also associated with decreased inflammation and an increase in the
number of FoxP3 positive cells in brain. In this study, tolerization to MBP prior to MCAO was
associated with a tendency to develop a TH1 response to MBP by 3 months after MCAO.
Conclusion: These data show that induction of immunological tolerance to MBP is associated with
improved outcome after stroke. This study, however, raises concern about the potential for
inadvertent induction of detrimental autoimmunity through mucosal administration of antigen.
Introduction
There is a complex interplay between the central nervous
system (CNS) and the systemic immune system; the
immune response appears to contribute to ischemic brain
injury and cerebral ischemia affects the systemic immune
response. Immediately after experimental stroke, periph-
eral blood lymphocytes and splenocytes become activated
and are capable of secreting massive amounts of pro-
inflammatory cytokines [1]. In concert with this systemic
response, there is inflammation within the injured brain,
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the brain improve outcome from experimental stroke [2].
Modulation of the immune response following stroke,
however, has yet to translate into clinical benefit.
Despite the initial inflammatory response in the brain and
periphery after stroke, the immune system later becomes
incapable of adequately responding to pathogens, predis-
posing animals to infection [3]. One potential benefit of
this "systemic immunodepression" is that it limits the
chance of developing an autoimmune response to the
brain antigens exposed to the immune system by brain
injury [4]. In fact, we previously showed that if an
immune response to CNS antigens occurs following
experimental stroke, it is usually that of a regulatory
response (TREG) [5]. By inducing systemic inflammation
in the peri-infarct period, however, there appears to be a
fundamental change in how the immune system responds
to the CNS antigens exposed in injured brain; a detrimen-
tal autoimmune response emerges, and this autoimmune
response is associated with worse functional outcome 1
month after middle cerebral artery occlusion (MCAO)
[5,6]. This observation may help explain why patients
who experience infection in the immediate post-stroke
period have increased morbidity and mortality. Using the
paradigm of mucosal tolerance, however, we demon-
strated that induction of a TREG response to the brain anti-
gen myelin basic protein (MBP) prior to cerebral ischemia
could prevent development of the deleterious autoim-
mune response to this antigen and improve outcome (as
assessed 1 month after MCAO)[6] There are, however,
documented concerns about the long term consequences
of mucosal tolerance/immune deviation therapy [7-9]. In
the current experiments, we extended the period of follow
up to 3 months after MCAO to assess for adverse out-
comes; immunocytochemistry (ICC) was also performed
to assess the degree of cellular inflammation in the brain.
Materials and methods
Animals
Experiments were approved by the Institution's Animal
Care and Use Committee. Male Lewis rats (250 to 300 g)
were used for all studies. Rats were handled prior to tests/
surgical procedures and housed 3 per cage to eliminate
differences in socialization.
Tolerization Schedule
The experimental paradigm is outlined in Figure 1a. Prior
to sham surgery or stroke, either bovine MBP (100 μg/40
μl; N = 30) or ovalbumin (OVA; 100 μg/40 μl; N = 29) was
instilled into each nostril every other day for a total of 5
doses; surgery was performed 1-2 days after the last instil-
lation. (Heterologous MBP has been repeated shown to
induce immunologic tolerance to MBP which is "clini-
cally" meaningful [10].)
Middle Cerebral Artery Occlusion (MCAO)
Anesthesia was induced with 5% and maintained with
1.5% isoflurane. After midline neck incision, the right
common carotid, internal carotid and pterygopalantine
arteries were ligated. A monofilament suture (4.0) was
inserted into the common carotid artery and advanced
into the internal carotid artery [11]; 20 OVA tolerized and
25 MBP tolerized animals were subjected to MCAO. Ani-
mals were maintained at normothermia during surgery.
Reperfusion was performed 3 hours after MCAO. In
sham-operated animals (9 OVA tolerized and 5 MBP tol-
erized), the suture was inserted into the carotid but not
advanced. Rectal temperature and body weight were
assessed at set time intervals. Animals were sacrificed 3
Experimental paradigm (a)Figu e 1
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ous study in which animals were sacrificed at 1 month
after MCAO or sham-surgery are also included for refer-
ence [6].)
Lipopolysaccharide Administration
All animals received LPS (serotype 026:B6; 1 mg/kg intra-
peritoneally) 3 hours after MCAO (at reperfusion) or
sham surgery.
Neurological Outcome
Neurological status was assessed at set time points after
MCAO; tests included a modification of the Bederson
scale and an adaptation of the 'sticky tape test' [12,13].
Sensorimotor performance was assessed using a rotating
drum or "rotarod"; average time to fall (100 secs maxi-
mum) from a rod rotating at 5 rpms over three trials was
recorded. Data for non-surviving animals are included to
the time of their death.
ELISPOT Assays
Animals for ELISPOT were sacrificed 3 months after
MCAO/sham surgery and mononuclear cells (MNCs) iso-
lated from the brain and spleen using previously
described methods [5,14]. MNCs were cultured (1 × 105
cells/well) for 48 hours in 96-well plates (MultiScreen®-IP;
Millipore) in media alone or in media supplemented with
MBP (25 μg/mL) or OVA (25 μg/mL). All experiments
were performed in triplicate. Antigen specific secretion of
IFN-γ (in comparison to unstimulated cells) was used as
an indicator of the TH1 response; antigen specific secre-
tion of TGF-β1 was used as an indicator of the TREG
response. Spots were counted under a dissecting micro-
scope by two independent investigators blinded to treat-
ment status. The ratio of the increase in the number of
MBP or OVA-specific cells secreting IFN-γ to that of the
increase in MBP or OVA-specific cells secreting TGF-β1
was determined. Based on previous data from our labora-
tory, the lower interquartile range for this ratio in animals
sensitized to MBP (by injection in complete Freund's
adjuvant) was 1.48 [15]. We thus considered animals to
have a TH1(+) response to MBP if the ratio of the IFN:TGF
response was ≥ 1.48; conversely, a TREG was considered to
be induced if this ratio was ≤ 0.68 (ie. 1.00 ÷ 1.48).
The number of ELISPOT assays performed on MNCs from
brain was less than that on spleen given that some brains
were frozen for ICC (N = 8 for OVA tolerized and N = 17
for MBP tolerized animals subjected to MCAO and N = 6
for OVA tolerized and N = 3 for MBP tolerized animals
subjected to sham-surgery).
Enzyme-Linked ImmunoSorbent Assays (ELISAs)
Blood was collected by cardiac puncture at the time of sac-
rifice. Serum was stored at -80° until use. Fractalkine lev-
els were assessed using a commercially available kit (R&D
Systems). Titers of IgG antibodies specific for MBP were
measured using indirect ELISA; data are presented as rela-
tive absorption units.
Immunocytochemistry
Brains were snap frozen in isopentane and sections (20
μm) stored at -80°C until use. The following monoclonal
antibodies were used: clone W3/25 (AbD Serotec)
directed against CD4 in T cells, clone OX-8 (AbD Serotec)
directed against CD8 in T cells, clone OX-33 to detect
CD45 on B cells (GenWay), clone #10/78 directed against
CD161 on natural killer (NK) cells (Serotec), and clone #
FJK-16s directed against Foxp3 (eBioscience). Sections
were fixed in acetone and blocked with Superblock buffer
(Thermo Scientific); ICC was performed using the immu-
noperoxidase method and sections were counterstained
with cresyl violet. The numbers of positively stained cells
were quantified on coronal brain slices corresponding to
the center of the infarct (bregma -0.26 mm). Cells were
counted in 6 different high power (100×) fields at 4 differ-
ent locations in both the infarcted (1-4) and non-inf-
arcted hemisphere (5-8); Figure 1b depicts these areas.
Hemispheric volume was determined using NIH image
and expressed as the ratio between the ischemic and non-
ischemic hemisphere.
Statistics
Categorical data were evaluated using the χ2-test statistic.
Parametric data were compared using the t-test, paired t-
test or analysis of variance (ANOVA) and are expressed as
mean ± standard error of the mean (SEM). Non-paramet-
ric data were compared using the Mann-Whitney U-test.
Significance was set at P ≤ 0.05.
Results
MBP versus OVA tolerized Animals
Following MCAO, mortality was higher in OVA (7/20)
than MBP (1/25) tolerized animals (P = 0.007). All deaths
occurred within 24 hours of MCAO except for 1 OVA tol-
erized animal that died between months 2 and 3. Among
surviving animals, the temperatures did not differ at any
point after stroke (data not shown). There was a general
trend towards MBP tolerized animals to regain weight
faster than OVA tolerized animals and to perform better
on tests of functional outcome, but these differences were
not sustained (Figure 2).
There were more splenocytes in MBP than OVA tolerized
animals (13.8 × 108 ± 3.1 × 108 vs. 5.5 × 108 ± 1.1 × 108; P
= 0.018) at sacrifice; the numbers of brain monocytes in
MBP and OVA tolerized animals were similar. The con-
centrations of circulating fractalkine and MBP antibodies
were also similar in MBP and OVA tolerized animals
undergoing MCAO.Page 3 of 10
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tolerized animals died (NS). There were no differences in
the temperatures, neurological scores or performance on
behavioral tests (sticky tape test and rotarod) of MBP and
OVA tolerized sham-operated animals at any time point
after surgery. The concentrations of circulating fractalkine
and MBP antibodies at the time of sacrifice did not differ
between sham-operated MBP tolerized and sham-oper-
ated OVA tolerized animals.
Sham-operated animals performed markedly better on all
behavioral outcome measures than their counterparts
undergoing MCAO. Three months after surgery, OVA tol-
erized animals undergoing MCAO had higher titers of
MBP antibodies than OVA tolerized animals undergoing
sham surgery (0.345 ± 0.053 vs. 0.187 ± 0.021 relative
units; P = 0.015); antibody titers to MBP were similar
among ischemic and sham-operated MBP tolerized ani-
mals.
Cellular responses in Sham-Operated Animals
Among sham-operated animals, mucosal administration
of OVA was associated with a significantly attenuated TH1
response to OVA in spleen at 1 month in comparison to
non-OVA tolerized animals (0.67 ± 0.06 vs. 1.20 ± 0.17; P
= 0.004); at 3 months, these differences were no longer
apparent. The immune response to OVA in brain did not
differ between OVA tolerized and non-OVA tolerized
sham-operated animals. Similarly, animals tolerized to
MBP had an attenuated TH1 response to MBP in spleen at
1 month after sham surgery (0.70 ± 0.12 vs. 1.03 ± 0.09; P
= 0.05); at 3 months, these differences were no longer
apparent. The immune response to MBP in brain did not
differ between MBP tolerized and OVA tolerized sham-
operated animals. In both OVA tolerized and MBP toler-
ized animals, there was an increase in the TH1 response to
the respective antigens in spleen from 1 month to 3
months; 0.67 ± 0.06 vs. 1.70 ± 0.17; P = 0.001 for OVA
and 0.70 ± 0.12 vs. 1.12 ± 0.12; P = 0.07 for MBP.
TH1 responses following MCAO
The cellular immune responses to OVA in both brain and
spleen were similar in OVA tolerized and non-OVA toler-
ized animals following MCAO at 1 month and 3 months
following MCAO; immune responses to OVA were not
predictive of outcome at either time point. We previously
showed that induction of mucosal tolerance to MBP prior
to MCAO and LPS administration prevented the post-
ischemic TH1 response to MBP at 1 month [6]. In the cur-
rent study where animals were examined 3 months after
MCAO, however, no differences were seen between MBP
and OVA tolerized animals in either the proportion of ani-
mals developing a TH1(+) response to MBP or the magni-
tude of that response (Table 1 and Figure 3). (Data from
our 1 month study are also displayed in Table 1 and Fig-
ure 3; comparison of these data show that the proportion
of MBP tolerized animals that developed a TH1(+)
response to MBP in brain is higher at 3 months than at 1
month.)
There was no difference in performance on the rotarod
among animals with or without a TH1(+) response to
MBP in brain (Figure 4a). Animals with a TH1(+) response
to MBP in spleen, however, performed worse on the
rotarod at 3 months after stroke onset (Figure 4b). Among
animals considered to have a TH1(+) response to MBP in
brain, there was a strong correlation between the degree of
that response and the time it took to attend to a piece of
MBP tolerized animals perform better on the rotarod (a), demonstrate quicker recognition of adhesive tape on the paw (b) and gain weight more rapidly (c) than OVA tolerized animals up to 1 month after MCAO; the benefits ar  no longer apparent t 3monthsFigur  2
MBP tolerized animals perform better on the rotarod (a), demonstrate quicker recognition of adhesive tape 
on the paw (b) and gain weight more rapidly (c) than OVA tolerized animals up to 1 month after MCAO; the 
benefits are no longer apparent at 3 months. Point estimates represent the mean and the bars represent the standard 
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with a TH1(+) response to MBP in spleen, there was a sim-
ilar correlation between the degree of TH1(+) response to
MBP in spleen and performance on the sticky tape test (r
= 0.965; P < 0.001).
Our previous data suggested that circulating levels of frac-
talkine might be a useful marker of an ongoing immune
response in brain at 1 month after MCAO[6] At 3 months,
however, there were no differences in the concentrations
of circulating fractalkine among animals with a TH1(+)
response to MBP (in either spleen or brain) and those
without. Higher concentrations of fractalkine were, how-
ever, associated with higher titers of anti-MBP antibodies
(r = 0.413, P = 0.021) (Figure 4c) and increased brain atro-
phy (r = 0.879, P = 0.004) (Figure 4d). There was also a
modest correlation between the cellular immune
response to MBP and the humoral response to MBP (r =
0.395, P = 0.028).
TREG Response to MBP following MCAO
At one month after MCAO, animals tolerized to MBP were
more likely to evidence a TREG response to MBP than ani-
mals tolerized to OVA [6]. In the current study, however,
we found that a TREG response to MBP was difficult to
detect 3 months after MCAO. Only 6/22 (27%) MBP tol-
erized (and 1/13 [8%] OVA tolerized) animals evidenced
a TREG response to MBP in spleen; the number of animals
with a TREG response to MBP in brain was even smaller (3/
17 [18%] MBP tolerized and 0/8 OVA tolerized animals)
(Table 1). As shown in Figure 5, animals with a TREG
response to MBP in either brain or spleen tended to have
longer latencies to fall from the rotarod (Figure 5a, b),
react more quickly to a stimulus on their paw (Figure 5c,
d) and regain weight more quickly (Figure 5e, f) than ani-
mals without a TREG response.
Inflammatory Infiltrates in Brain
In a subgroup of animals, ICC was performed on brain.
There were no differences in the number of CD4+, CD8+,
CD45+, CD161+, or Foxp3+ cells in the ischemic hemi-
sphere (regions 1-4; Figure 1b) of MBP tolerized and non-
Individual animal data showing the number of MBP specific IFN and TGF secreting cells in brain (a) and spleen (b) among OVA and MBP tolerize  animals ( o e the diff ence in the scales on the Y-axi )Figure 3
Individual animal data showing the number of MBP specific IFN and TGF secreting cells in brain (a) and spleen 
(b) among OVA and MBP tolerized animals (note the difference in the scales on the Y-axis). The magnitude of the 
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mals, however, had fewer CD4+ cells in the non-ischemic
hemisphere of (P = 0.036). Animals with a TREG response
to MBP in spleen (N = 2) had fewer CD4+, fewer CD45+
and more Foxp3+ cells in the infarcted hemisphere than
those without a TREG response (N = 6); in the non-
ischemic hemisphere, the numbers of these cells were
similar in animals with and without a TREG response (Fig-
ure 6). The numbers of CD8+ and CD161+ cells did not
differ between animals with and without a TREG response
to MBP.
Discussion
Previous studies demonstrated that mucosal administra-
tion of CNS or vascular antigens in experimental stroke
was associated with decreased infarct volume and
improved outcome in the hours to days after stroke onset
[14,16-19]. We recently showed that the benefits of induc-
ing mucosal tolerance to brain antigens (ie. MBP) extend
to at least 1 month after MCAO [6]. In the current study,
however, we find that this benefit does not extend to 3
months after MCAO. Similar to findings in our previous
study, MBP tolerized animals evidenced improved per-
formance on the rotarod and appeared to regain weight
more quickly than OVA tolerized animals up to 1 month
after MCAO, but this benefit was not sustained past the 1
month mark (Figure 2). One possible explanation for this
disparity is that induction of mucosal tolerance to MBP
only hastens recovery from stroke, and that OVA tolerized
animals "catch up" over time. Another possible explana-
tion for the loss of benefit after 1 month is that the initial
treatment (mucosal administration of MBP) leads to a
delayed worsening of function. Indeed, if one compares
the performance of MBP tolerized animals on the rotarod
at 4 weeks after MCAO to that at later time points (Figure
2a), it suggests that there is a deterioration in function
after 1 month.
The paradigm for induction of tolerance in this study was
successful in attenuating the TH1 response to the antigen
administered, as demonstrated by the immune responses
in sham-operated animals at 1 month after surgery. By 3
months after sham-surgery, however, the effect of the tol-
erizing regimen could no longer be detected (in fact, there
was an increase in the TH1 response to the antigen to
which the animal was "tolerized"). Following MCAO, we
detected a higher proportion of MBP tolerized animals
with a TH1(+) response to MBP at 3 months than at 1
month. This finding raises the possibility that mucosal
administration of (auto) antigens could induce detrimen-
tal autoimmune responses. It is important to note that the
animals in these studies received LPS at the time of
MCAO; it is unclear whether the same tendency toward at
TH1(+) response to MBP would be seen in MBP tolerized
animals that had not been treated with LPS.
Based on experimental data, there are compelling reasons
to pursue mucosal tolerance as a therapy for patients with
a variety of autoimmune diseases. The results of clinical
studies to date, however, have been disappointing
[20,21]. While there are many potential explanations for
the failure of mucosal tolerance in clinical trials, there is
concern that mucosal administration of antigen can, at
least in some instances, lead to detrimental autoimmu-
nity. For instance, mucosal administration of antigen dur-
ing experimental autoimmune encephalomyelitis (EAE)
may exacerbate inflammation and oral administration of
high dose insulin may induce autoimmune diabetes [7,8].
In addition, it is known that mucosal administration of
antigen can induce antibody production (a Th2 response)
Table 1: Immune status at 1 and 3 months following middle cerebral artery occlusion.










TH1 6 (35) 1 (6) 0.033 4 (50) 6 (35) NS NS 0.041










TH1 8 (38) 1 (6) 0.001 6 (46) 5 (23) NS NS 0.089
TREG 0 7 (33) 0.001 1 (8) 6 (27) NS NS NS
Animals are considered to have a TH1(+) response to MBP if the ratio of the relative increase in the number of MBP-specific IFN secreting cells to 
the relative increase in the number of MBP-specific TGF secreting cells is at least 1.48. Conversely, they are considered to have a TREG response to 
MBP if the ratio of the relative increase in the number of MBP-specific IFN secreting cells to the relative increase in the number of MBP-specific 
TGF secreting cells is ≤ 1 ÷ 1.48 (0.68).Page 6 of 10
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responses may also be detrimental, as demonstrated in a
non-human primate model of EAE where therapy with
soluble myelin oligodendrocyte glycoprotein (MOG) was
associated with the late development of pathogenic MOG
antibodies [9]. A major and important difference between
most laboratory studies and clinical trials is the duration
of follow up. In the laboratory setting, animals are gener-
ally followed for only a short duration of time; in the clin-
ical arena, patients are generally followed for a much
longer period of time and there is more opportunity for
toxicities to emerge.
In this study we considered MBP specific induction of
IFN-γ as the marker for the TH1 response and MBP specific
induction of TGFβ-1 as the marker for the inducible TREG
response; animals that evidenced a TH1 response to MBP
had worse outcome from stroke while those that evi-
denced a TREG response to MBP had better outcome. There
is now a robust literature suggesting that TH17 cells are the
key effector cells in many autoimmune diseases [24]. Fur-
ther, the ratio of antigen specific TH17 to TH1 cells can
determine the nature of the autoimmune disease [25].
Future studies will need to address the role of TH17 cells
in our stroke model. As mentioned, inducible TREG cells
are characterized by antigen specific secretion of TGFβ-1
[21,26]; inducible TREG cells also secret IL-10 [27]. Irre-
The TH1 response to MBP in brain is not predictive of rotarod performance (a), but animals with a TH1 response to MBP in spl en hav  a shorter latency to fall from th  ro arod (ie. worse performance) 3 months after MCAO than animals without a H1 respon e to MBP in spleen (b)Figu  4
The TH1 response to MBP in brain is not predictive of rotarod performance (a), but animals with a TH1 
response to MBP in spleen have a shorter latency to fall from the rotarod (ie. worse performance) 3 months 
after MCAO than animals without a TH1 response to MBP in spleen (b). Point estimates represent the mean and the 
bars represent the standard error of the mean (*P < 0.05 using the t-test). There is a correlation between the humoral 
response to MBP (antibody titer) and the concentration of circulating fractalkine (c) and the concentration of circulating frac-
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evidence a TREG response to MBP appear to have a better
outcome from MCAO [6,14,16-19]. These data further
support the fact that the immune response to CNS anti-
gens affects outcome from experimental stroke.
Given the apparent importance of a TREG response to MBP
for good outcome from MCAO, a viable therapeutic strat-
egy would be one that is associated with an enhanced and
sustained increase in the TREG response to defined brain
antigens. That we were unable to demonstrate a signifi-
cant difference in the proportion of MBP and OVA toler-
ized animals with a TREG response to MBP at 3 months
may relate to the possibility that MBP treated animals
"deviated" towards a TH1 response by 3 months, as
already discussed. While functional TREG cells can be
found within a few days of mucosal antigen administra-
tion [28], T cell function begins to normalize after several
weeks [29]. The loss of the TREG response to both OVA
and MBP among sham-operated OVA tolerized and MBP
tolerized animals, respective, at 3 months is consistent
with this "normalization of function". Studies have
shown that "booster" doses of antigen can be used to sus-
tain the beneficial effects of mucosal tolerance [18,30,31].
In concert, these findings suggest that induction of CNS
specific TREG cells after stroke may be an effective stroke
therapy, but this induction must be done in a manner that
leads to a sustained population of these regulatory cells
and does not carry a risk of precipitating subsequent dele-
terious autoimmunity.
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Animals with a demonstrated TREG response to MBP perform better on the rotarod (a, b), have shorter 
latency to react to adhesive tape on the paw (c, d) and regain weight faster (e, f) than animals without a TREG 
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